Nadege Corradini

10PUBLICATIONS
131CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursMolecular targetsImmunogenetics (incl. genetic immunology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Jan 27, 2026
Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial.

Susanne A Gatz, Pablo Berlanga, Gwénaël Le Teuff

|Dec 12, 2025
Dinutuximab Beta Added to Temozolomide-Based Chemotherapy for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON Immuno Phase II Trial.

Juliet C Gray, Rebekah Weston, Cormac Owens

|Nov 17, 2025
Interest of a sequential multimodal approach for the treatment of newly diagnosed patients with multimetastatic Ewing sarcoma: results of the French prospective CombinaiR3 phase II trial.

Valérie Laurence, Nina Jehanno, Sylvain Dureau

|May 24, 2024
Sequential Analysis of cfDNA Reveals Clonal Evolution in Patients with Neuroblastoma Receiving ALK-Targeted Therapy.

Charles Bobin, Yasmine Iddir, Charlotte Butterworth

|Jan 08, 2024
Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial.

Lucas Moreno, Rebekah Weston, Cormac Owens

|Oct 19, 2023
Inflammatory Myofibroblastic Tumor With ROS1 Gene Fusions in Children and Young Adolescents.

Reineke A Schoot, Daniel Orbach, Veronique Minard Colin

Pageof 2

Frequent Collaborators

4 joint publications

Pascal Chastagner

4 joint publications

Guy Makin

3 joint publications

Francisco J Bautista

3 joint publications

Gaelle Pierron